Episurf Medical enters into a distribution agreement for additional markets in Asia
Episurf Medical (Nasdaq: EPIS B) today announces that the company has entered into a distribution agreement with Humedical (S) Pte Ltd. The agreement covers the markets in Singapore, Malaysia, and Brunei. Episurf Medical is currently working with obtaining regulatory clearances in said markets, and these processes are expected to be completed during the first quarter of 2021.
Humedical (S) Pte Ltd has for 25 years been operating as a supplier to a significant part of the hospitals in the region, focusing on surgery, including orthopaedics.
“We are happy to be able to enter into a partnership with such an experienced and well-established distributor as Humedical, as we are systematically preparing for product launch in new markets in Asia” says Pål Ryfors, CEO Episurf Medical.
Episurf Medical has since before a distributor agreement in place for Hong Kong.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.